Fundraisings and IPOs

Date: 2018-10-10

Type of information: IPO

Company: Allogene Therapeutics (USA - CA)


Amount: $324 million

Funding type: IPO

Planned used:


  • • On October 10, 2018, Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced the pricing of its initial public offering of 18,000,000 shares of its common stock at a price to the public of $18.00 per share.
  • The gross proceeds to Allogene Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $324.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on October 11, 2018 under the symbol "ALLO."
  • The offering is expected to close on October 15, 2018, subject to customary closing conditions. In addition, Allogene Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of common stock.
  • Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC are acting as the joint book-running managers for the offering.

Therapeutic area: Cancer - Oncology

Is general: Yes